Previous 10 | Next 10 |
I-Mab Filed 2020 Annual Report on Form 20-F PR Newswire SHANGHAI and GAITHERSBURG, Md. , April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...
I-Mab (IMAB) is trading ~1.9% higher in the pre-market after announcing positive topline results for olamkicept (TJ301) in a phase 2 study (NCT03235752) involving patients with active ulcerative colitis (UC).The multi-center, randomized, double-blind, and placebo...
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis PR Newswire SHANGHAI and GAITHERSBURG, Md. , April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Earnings reports will dominate the action next week even as investors keep a watch for any developments with an infrastr...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on pr...
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments. Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 anti...
Research company Shanghai Genechem announces a global collaboration with I-Mab ([[IMAB]] +0.2%) to develop and commercialize multiple bi-specific antibodies ((BsAb)) based on monoclonal antibody developed by Genechem and antibodies selected by I-MAB. "This collaboration i...
I-Mab (IMAB) and South Korean biotech ABL Bio announce that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL503.The trial is an open-label, multi-center, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics ((PK...
SHANGHAI, China and GAITHERSBURG, Md. and SEONGNAM, South Korea, April 06, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, I...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...